Literature DB >> 11493612

IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcepsilonRI in human basophils.

D MacGlashan1, H Z Xia, L B Schwartz, J Gong.   

Abstract

Expression of the high-affinity receptor on basophils and mast cells is modulated by immunoglobulin E (IgE) antibody. Recent studies have shown that modulation occurs through interaction of IgE with the receptor itself, but the mechanisms underlying this control are not understood. Taking both a theoretical and experimental approach, we examined several competing models that focus on whether there is IgE-regulated loss, IgE-regulated synthesis, or both regulated loss and synthesis of the Fc receptor for IgE (FcepsilonRI). We report that removing IgE from occupied FcepsilonRI resulted in an accelerated loss only in the unoccupied receptor, with no loss of occupied receptors and no loss of total receptors when all receptors were occupied. Together with previous studies, these results establish that there was IgE-regulated loss of receptors. An examination of synthetic rates of FcepsilonRIalpha using pulse-labeling with (35)S-methionine indicated no difference in synthetic rates in the presence or absence of IgE. Similarly, the presence or absence of IgE had no influence on the levels of mRNA for either alpha, beta, or gamma subunits of FcepsilonRI. Using model simulations, we found that regulated-synthesis models could be distinguished from regulated-loss/constant-synthesis models on the basis of the relationship between starting FcepsilonRI densities and changes in density after culture for 1 week in the absence of IgE. Experimental data from this type of study fit a regulated-loss model that did not include regulation of synthesis. Taken together, these results suggest that IgE regulates cell surface expression of FcepsilonRI only by regulating the rate that receptor is lost from the cell surface.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493612

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  26 in total

Review 1.  IgE and FcepsilonRI regulation.

Authors:  Donald MacGlashan
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

2.  Serum IgE clearance is facilitated by human FcεRI internalization.

Authors:  Alexandra M Greer; Nan Wu; Amy L Putnam; Prescott G Woodruff; Paul Wolters; Jean-Pierre Kinet; Jeoung-Sook Shin
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

Review 3.  Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease.

Authors:  Monica G Lawrence; Judith A Woodfolk; Alexander J Schuyler; Leland C Stillman; Martin D Chapman; Thomas A E Platts-Mills
Journal:  J Allergy Clin Immunol       Date:  2016-07-14       Impact factor: 10.793

Review 4.  Pros and Cons of Clinical Basophil Testing (BAT).

Authors:  Hans Jürgen Hoffmann; Edward F Knol; Martha Ferrer; Lina Mayorga; Vito Sabato; Alexandra F Santos; Bernadette Eberlein; Anna Nopp; Donald MacGlashan
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

5.  Stability of Syk protein and mRNA in human peripheral blood basophils.

Authors:  Donald MacGlashan
Journal:  J Leukoc Biol       Date:  2016-03-15       Impact factor: 4.962

6.  Helminth infection is associated with decreased basophil responsiveness in human beings.

Authors:  David Larson; Philip J Cooper; Marc P Hübner; Jorge Reyes; Maritza Vaca; Martha Chico; Heidi H Kong; Edward Mitre
Journal:  J Allergy Clin Immunol       Date:  2012-05-16       Impact factor: 10.793

7.  Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophils.

Authors:  Susan S Ishmael; Donald W MacGlashan
Journal:  J Leukoc Biol       Date:  2009-11-04       Impact factor: 4.962

8.  Expression of the high affinity IgE receptor by neutrophils of individuals with allergic asthma is both minimal and insensitive to regulation by serum IgE.

Authors:  Juanita Mora; Emily K Riggs; Jun Fu; Donald W MacGlashan; Susan A Fox; Byung Yu; Mary C Tobin; Larry L Thomas
Journal:  Clin Immunol       Date:  2009-04-08       Impact factor: 3.969

9.  Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.

Authors:  Janet M Oliver; Christy A Tarleton; Laura Gilmartin; Tereassa Archibeque; Clifford R Qualls; Lorena Diehl; Bridget S Wilson; Mark Schuyler
Journal:  Int Arch Allergy Immunol       Date:  2009-10-22       Impact factor: 2.749

10.  Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue.

Authors:  Joke Patou; Gabriele Holtappels; Karen Affleck; Philippe Gevaert; Claudina Perez-Novo; Paul Van Cauwenberge; Claus Bachert
Journal:  J Inflamm (Lond)       Date:  2009-04-20       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.